Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA 3rd, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK. Han LY, et al. Among authors: dalgarno dc. Cancer Res. 2006 Sep 1;66(17):8633-9. doi: 10.1158/0008-5472.CAN-06-1410. Cancer Res. 2006. PMID: 16951177 Free PMC article.
SRC inhibitors in metastatic bone disease.
Boyce BF, Xing L, Yao Z, Yamashita T, Shakespeare WC, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK. Boyce BF, et al. Among authors: dalgarno dc. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6291s-6295s. doi: 10.1158/1078-0432.CCR-06-0991. Clin Cancer Res. 2006. PMID: 17062716 Review.
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T. O'Hare T, et al. Among authors: dalgarno dc. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028. Cancer Cell. 2009. PMID: 19878872 Free PMC article.
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D, Stehle T, Narula S, Schelling P, van Schravendijk MR, Adams S, Andrade L, Keats J, Ram M, Jin L, Grossman T, MacNeil I, Metcalf C 3rd, Shakespeare W, Wang Y, Keenan T, Sundaramoorthi R, Bohacek R, Weigele M, Sawyer T. Dalgarno D, et al. Chem Biol Drug Des. 2006 Jan;67(1):46-57. doi: 10.1111/j.1747-0285.2005.00316.x. Chem Biol Drug Des. 2006. PMID: 16492148
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Sundaramoorthi R, Shakespeare WC, Keenan TP, Metcalf CA 3rd, Wang Y, Mani U, Taylor M, Liu S, Bohacek RS, Narula SS, Dalgarno DC, van Schravandijk MR, Violette SM, Liou S, Adams S, Ram MK, Keats JA, Weigle M, Sawyer TK, Weigele M. Sundaramoorthi R, et al. Among authors: dalgarno dc. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3063-6. doi: 10.1016/s0960-894x(03)00647-4. Bioorg Med Chem Lett. 2003. PMID: 12941334
Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases.
Wang Y, Metcalf CA 3rd, Shakespeare WC, Sundaramoorthi R, Keenan TP, Bohacek RS, van Schravendijk MR, Violette SM, Narula SS, Dalgarno DC, Haraldson C, Keats J, Liou S, Mani U, Pradeepan S, Ram M, Adams S, Weigele M, Sawyer TK. Wang Y, et al. Among authors: dalgarno dc. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3067-70. doi: 10.1016/s0960-894x(03)00648-6. Bioorg Med Chem Lett. 2003. PMID: 12941335
Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Shakespeare WC, Metcalf CA 3rd, Wang Y, Sundaramoorthi R, Keenan T, Weigele M, Bohacek RS, Dalgarno DC, Sawyer TK. Shakespeare WC, et al. Among authors: dalgarno dc. Curr Opin Drug Discov Devel. 2003 Sep;6(5):729-41. Curr Opin Drug Discov Devel. 2003. PMID: 14579523 Review.
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ. Azam M, et al. Among authors: dalgarno dc. Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9244-9. doi: 10.1073/pnas.0600001103. Epub 2006 Jun 5. Proc Natl Acad Sci U S A. 2006. PMID: 16754879 Free PMC article.
78 results